Want to see KYNB full AI Analyst Report?
Top Page
Kyntra Bio
(NASDAQ:KYNB)
Select Model
Select Model
Rating:53Neutral
Price Target:
$7.50
▲(2.46% Upside)
Action:Reiterated
Date:06/17/26
The score is held back primarily by weak financial quality (ongoing operating losses, cash burn, and negative equity) and soft technical trend signals. These are partly offset by comparatively attractive P/E-based valuation, constructive earnings-call updates with defined clinical milestones and runway into 2028, and mixed corporate events where liquidity positives are tempered by Nasdaq compliance risk.
Positive Factors
Cash runway into 2028
A $100.3M liquidity position with management guidance to fund operations into 2028 materially lowers near-term financing risk and gives the company time to reach key clinical inflection points. That runway supports executing trials and regulatory interactions without immediate capital raises.
Negative Factors
Persistent negative operating cash flow
Consistent negative operating and free cash flow indicates the business continues to burn cash to fund operations and development. Even with current reserves, continued negative OCF elevates refinancing risk, constrains optionality for parallel programs, and increases dependency on external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash runway into 2028
A $100.3M liquidity position with management guidance to fund operations into 2028 materially lowers near-term financing risk and gives the company time to reach key clinical inflection points. That runway supports executing trials and regulatory interactions without immediate capital raises.
Read all positive factors
Kyntra Bio Key Performance Indicators (KPIs)
Any
Revenue by Segment
Analyzes revenue from different business areas, highlighting which segments drive growth and profitability, and identifying potential areas of strength or concern.
Analyzes revenue from different business areas, highlighting which segments drive growth and profitability, and identifying potential areas of strength or concern.
Data provided by:
The Fly
The FlyKyntra Bio (KYNB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$29.92M
Dividend YieldN/A
Average Volume (3M)30.76K
Price to Earnings (P/E)0.2
Beta (1Y)0.81
Revenue Growth-92.77%
EPS GrowthN/A
CountryUS
Employees34
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)41.56
Shares Outstanding4,048,112
10 Day Avg. Volume33,010
30 Day Avg. Volume30,760
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.18
Price to Sales (P/S)5.51
P/FCF Ratio-7.38
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$36.00Price Target Upside391.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-13.75
Revenue Forecast (FY)$7.94M
Kyntra Bio Business Overview & Revenue Model
Company Description
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves...
Kyntra Bio Earnings Call Summary
Earnings Call Date:May 11, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 10, 2026
Earnings Call Sentiment Positive
The call conveyed meaningful clinical progress across two key programs (FG-3246/FG-3180 and roxadustat), supportive subgroup efficacy data, validated mitigation of a key ADC safety issue, improved financial discipline with reduced R&D and SG&A, revenue growth, and a cash runway into 2028. Key risks include ongoing net losses, small revenue base, an unresolved biomarker statistical significance that 'just missed' in the IST, residual safety concerns around neutropenia, and reliance on upcoming binary clinical readouts and enrollment execution. On balance, the positives (clinical signals, validated mitigation strategy, constructive FDA feedback on roxadustat, cash runway and expense reductions) outweigh the lowlights, though the company remains dependent on near-term trial execution.Positive Updates
Revenue Growth
Total revenue of $3.7M in Q1 2026 vs $2.7M in Q1 2025, an increase of approximately 37% year-over-year.
Negative Updates
Ongoing Net Losses and Small Revenue Base
Despite improvements, the company reported a net loss of $15.1M in Q1 2026 and total revenue remains small at $3.7M, indicating continued dependence on financing or milestone-based funding until commercialization.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth
Total revenue of $3.7M in Q1 2026 vs $2.7M in Q1 2025, an increase of approximately 37% year-over-year.
Read all positive updates
Company Guidance
Kyntra provided clear near-term guidance: an interim analysis of the FG-3246/FG-3180 Phase II monotherapy trial (75 patients across 3 highest Phase I dose levels) is planned for Q4 2026 (will report PSA50, ORR, safety, PK and exposure‑response) with mature median rPFS data expected in 2027 and a target benchmark of ≥10 months (Phase I monotherapy rPFS = 8.7 months; Phase I PSA50 = 36%; ORR = 20% with DOR = 7.5 months; IST combo rPFS = 7.0 months overall and 10.1 months in patients with only 1 prior ARPI, PSA50 = 40% in that subgroup); FG-3180 PET showed a trend associating higher SUV with response (nominal p just missed significance) and could be used to select a CD46-high population for a Phase III (typically 400+ patients) if supported by Phase II; roxadustat Phase III (targeting ~49,000 U.S. lower‑risk MDS patients refractory/ineligible to ESAs) will use 8‑week transfusion independence as the primary endpoint (12‑ and 16‑week key secondaries), follows a post‑hoc MATTERHORN high‑burden result (36% vs 7% placebo, p=0.041), received constructive FDA feedback in April 2026 and is expected to initiate in H2 2026; financial runway extends into 2028 with $100.3M in cash, cash equivalents, investments and AR as of March 31, Q1 2026 revenue $3.7M, operating costs $17.6M, R&D $7.6M, SG&A $5.9M, and net loss $15.1M ($3.74/share).Kyntra Bio Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
42
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.44M | 6.44M | 29.62M | 46.80M | 140.73M | 235.31M |
| Gross Profit | 3.36M | 5.88M | 14.06M | 42.84M | 120.45M | -213.88M |
| EBITDA | -56.06M | -57.55M | -142.43M | -305.20M | -282.82M | -333.72M |
| Net Income | 163.62M | 183.45M | -47.58M | -284.23M | -293.65M | -290.02M |
Balance Sheet | ||||||
| Total Assets | 109.63M | 119.59M | 214.53M | 423.53M | 610.09M | 773.82M |
| Cash, Cash Equivalents and Short-Term Investments | 87.24M | 88.98M | 50.48M | 235.59M | 422.01M | 405.19M |
| Total Debt | 19.25M | 85.54M | 90.21M | 170.46M | 89.89M | 99.72M |
| Total Liabilities | 140.40M | 115.12M | 398.16M | 585.73M | 611.57M | 544.71M |
| Stockholders Equity | -43.80M | -30.04M | -225.60M | -204.17M | -21.45M | 209.15M |
Cash Flow | ||||||
| Free Cash Flow | -21.40M | -4.81M | -138.26M | -317.54M | -184.67M | -112.42M |
| Operating Cash Flow | -21.38M | -4.77M | -138.00M | -315.02M | -145.93M | -82.23M |
| Investing Cash Flow | 38.45M | 35.42M | 125.99M | 153.66M | 89.12M | -426.97M |
| Financing Cash Flow | -85.95M | -86.03M | -255.00K | 122.75M | 46.78M | -563.00K |
Kyntra Bio Technical Analysis
Positive
7.32
Price Trends
7.04
Positive
7.06
Positive
8.22
Negative
Market Momentum
0.11
Positive
54.48
Neutral
14.68
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYNB, the sentiment is Positive. The current price of 7.32 is above the 20-day moving average (MA) of 7.25, above the 50-day MA of 7.04, and below the 200-day MA of 8.22, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 54.48 is Neutral, neither overbought nor oversold. The STOCH value of 14.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KYNB.
Kyntra Bio Risk Analysis
Kyntra Bio disclosed 57 risk factors in its most recent earnings report. Kyntra Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kyntra Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $29.92M | 0.18 | -234.28% | ― | -92.77% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $165.62M | -0.95 | -61.02% | ― | ― | 25.85% | |
47 Neutral | $59.37M | -1.64 | -117.24% | ― | 476.71% | 70.23% | |
45 Neutral | $39.22M | -4.34 | -12.66% | ― | ― | 43.67% | |
44 Neutral | $14.32M | -0.24 | -503.79% | ― | ― | 82.28% |
* Healthcare Sector Average
KYNB
Kyntra Bio
7.23
-0.42
-5.49%
GRCE
Grace Therapeutics
2.47
-0.89
-26.49%
OKUR
OnKure Therapeutics
4.20
1.87
80.26%
SNTI
Senti Biosciences
0.44
-1.51
-77.59%
XLO
Xilio Therapeutics
8.88
-1.23
-12.15%
Kyntra Bio Corporate Events
Executive/Board ChangesShareholder Meetings
Kyntra Bio Shareholders Back Board, Pay and Auditor
Positive
Jun 16, 2026
At Kyntra Bio’s 2026 annual meeting of stockholders held on June 12, 2026, shareholders elected Class III director nominee Michael Kauffman, M.D., Ph.D., to serve until the 2029 annual meeting, with more than 96% of votes cast in favor, whil...
Business Operations and StrategyM&A Transactions
Kyntra Bio Receives Final Payment for China Divestiture
Positive
Jun 9, 2026
On August 29, 2025, Kyntra Bio closed the sale of its China operations, held through FibroGen International (Hong Kong) Ltd., to AstraZeneca for total consideration of approximately $220 million, including $85 million in enterprise value and about...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.